Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter - The Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) study | |
Article | |
关键词: LEFT-VENTRICULAR DYSFUNCTION; MYOCARDIAL-INFARCTION; ANTIARRHYTHMIC DRUG; RANDOMIZED TRIAL; THERAPY; AMIODARONE; QUINIDINE; MORTALITY; UK-68,798; | |
DOI : 10.1161/01.CIR.102.19.2385 | |
来源: SCIE |
【 摘 要 】
Background-This double-blind, multicenter, placebo-controlled study determined the efficacy and safety of dofetilide in converting atrial fibrillation (AF) or atrial flutter (AFl) to sinus rhythm (SR) and maintaining SR for 1 year. Methods and Results-Patients with AF or AFl (n=325) were randomized to 125, 2501 or 500 mug dofetilide or placebo twice daily. Dosages were adjusted for QTc response and, after 105 patients were enrolled, for calculated creatinine clearance (Cl-Cr). Pharmacological cardioversion rates for 125, 250, and 500 mug dofetilide were 6.1%, 9.8%, and 29.9%, respectively, versus 1.2% for placebo (250 and 500 mug versus placebo; P=0.015 and P<0.001, respectively). Seventy percent of pharmacological cardioversions with dofetilide were achieved in 24 hours and 91% in 36 hours. For the 250 patients who successfully cardioverted pharmacologically or electrically, the probability of remaining in SR at 1 year was 0.40, 0.37, 0.58 for 125, 250, and 500
【 授权许可】
Free